Andrew L. Feldman

Andrew L. Feldman, MD, is a Professor of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota. He specializes in the molecular pathogenesis of T-cell lymphomas, focusing on genetic abnormalities, biomarkers, and individualized therapies. His work bridges next-generation sequencing (NGS) infrastructure and translational research to improve lymphoma diagnosis and subclassification.

• Primary Appointment: Consultant, Division of Hematopathology
• Joint Appointment: Consultant, Division of Experimental Pathology and Laboratory Medicine

Education:

• MD, Brown University (1991)
• BA, Brown University (1986)
• Clinical Fellowship, Hematopathology, National Cancer Institute (2006)

Research Interests:
Dr. Feldman's research explores the genetic basis of T-cell lymphomas, which are often fatal. By characterizing mutations (e.g., DUSP22, TP63, STAT3) and applying bioinformatics, his team develops diagnostic tests to predict therapeutic responses. He also investigates how genetic heterogeneity impacts lymphoma classification and treatment strategies.

Scientific Awards:

• Berard-Dorfman Founders Award, Society for Hematopathology (2015)
• Recipient Medal, Pedro Ruiz Gallo National University, Peru (2007)
• Artemis Fellowship, Nikolas Symposium XV, Athens (2005)
• NIH Fellows Award for Research Excellence (2003, 2000)
• First Prize, Resident Paper Competition (1999)
• Daland Award, New England Cancer Society (1999)
• Outstanding Junior Resident Teaching Award (1996)
• Joseph Collins Foundation Scholarship (1988)

Advising and Grants:
Dr. Feldman has directed the Mayo Clinic Biospecimens Core and led NCI-funded projects like the Lymphoma Specialized Program of Research Excellence (SPORE) and Molecular Classification of Anaplastic Large Cell Lymphoma. He has served on NCI Lymphoma Steering Committee and Mayo Clinic's NGS Infrastructure Subcommittee.

Laboratory and Collaborations:
His lab collaborates with the International Lymphoma Study Group, Mayo Clinic Comprehensive Cancer Center, and Association for Molecular Pathology. He co-developed clinical trials linking molecular profiling to therapeutic targets and contributed to the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) Research Consortium.